Avidity Biosciences Inc (NASDAQ: RNA) is 166.30% higher on its value in year-to-date trading and has touched a low of $4.82 and a high of $26.24 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RNA stock was last observed hovering at around $24.24 in the last trading session, with the day’s loss setting it -0.14%.
Currently trading at $24.10, the stock is 20.36% and 58.33% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.08 million and changing -0.58% at the moment leaves the stock 141.48% off its SMA200. RNA registered 16.71% gain for a year compared to 6-month gain of 241.36%. The firm has a 50-day simple moving average (SMA 50) of $139.72 and a 200-day simple moving average (SMA200) of -$5.72.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 67.48% loss in the last 1 month and extending the period to 3 months gives it a 164.54%, and is 0.54% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.59% over the week and 8.18% over the month.
Avidity Biosciences Inc (RNA) has around 253 employees, a market worth around $1.92B and $9.56M in sales. Profit margin for the company is -2219.87%. Distance from 52-week low is 399.48% and -8.16% from its 52-week high. The company has generated returns on investments over the last 12 months (-41.86%).
Avidity Biosciences Inc quarterly earnings per share for the current quarter are estimated at -$0.78 with sales reaching $2.93M over the same period.The EPS is expected to shrink by -10.57% this year, but quarterly earnings will post 7.10% year-over-year. Quarterly sales are estimated to grow 31.20% in year-over-year returns.
209 institutions hold shares in Avidity Biosciences Inc (RNA), with institutional investors hold 91.26% of the company’s shares. The shares outstanding are 79.28M, and float is at 70.74M with Short Float at 10.98%. Institutions hold 85.40% of the Float.
The top institutional shareholder in the company is FMR, LLC with over 10.62 million shares valued at $117.81 million. The investor’s holdings represent 14.34% of the RNA Shares outstanding. As of Jun 29, 2023, the second largest holder is RTW Investments LP with 6.69 million shares valued at $74.19 million to account for 9.03% of the shares outstanding. The other top investors are Price (T.Rowe) Associates Inc which holds 6.68 million shares representing 9.02% and valued at over $74.13 million, while RA Capital Management, L.P. holds 8.66% of the shares totaling 6.42 million with a market value of $71.16 million.
Avidity Biosciences Inc (RNA) Insider Activity
The most recent transaction is an insider sale by LEVIN ARTHUR A, the company’s Director. SEC filings show that LEVIN ARTHUR A sold 5,000 shares of the company’s common stock on Mar 19 ’24 at a price of $23.97 per share for a total of $0.12 million. Following the sale, the insider now owns 14830.0 shares.
Avidity Biosciences Inc disclosed in a document filed with the SEC on Mar 13 ’24 that MacLean Michael F (Chief Financial Officer) sold a total of 40,000 shares of the company’s common stock. The trade occurred on Mar 13 ’24 and was made at $24.52 per share for $0.98 million. Following the transaction, the insider now directly holds 44093.0 shares of the RNA stock.
Still, SEC filings show that on Mar 12 ’24, Boyce Sarah (President and CEO) disposed off 28,000 shares at an average price of $22.63 for $0.63 million. The insider now directly holds 112,117 shares of Avidity Biosciences Inc (RNA).
